Caplight Directory>Companies>GPCR Therapeutics-preview>Gpcr-therapeutics


GPCR Therapeutics

GPCR Therapeutics

Private
South KoreaHealthcare & Life Scienceshttps://www.gpcr.co.kr

Last Round

Series C

Extension

Nov 23, 2023

Est. Valuation

$80.64M

Total Funding Raised

$55.78M

Momentum Score

25 /100

Company Overview

GPCR Therapeutics is a biopharmaceutical company focused on developing innovative therapeutics for cancer, utilizing novel science of heteromers to address unmet medical needs in treatment options.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

GPCR heteromersGPRC5D CAR-TCAR-T therapymultiple myelomadrug discovery platformG protein-coupled receptorGPCRGPRC5D targetchimeric antigen receptor T-celltargeted therapyclinical-stage biotechoncologycell therapydrug licensingantibody-based therapeuticsidiopathic pulmonary fibrosis

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GPCR Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

GPCR Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionNov 23, 2023
Series CJun 30, 2021
Series BJul 31, 2019
Series ASep 30, 2016
View all Funding Rounds

GPCR Therapeutics Investors

Notable investors and investment history

InvestorRounds
InterVestSeries C, Series A
Kinggo Investment PartnersSeries C Extension
Smilegate InvestmentSeries B
SUNP CorporationSeries C
Company K PartnersSeries C, Series A
Medytox Venture InvestmentSeries B, Series C Extension
LSK InvestmentSeries C Extension
View all Investors

GPCR Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

GPCR Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about GPCR Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth Korea
Employee Range15
Year Founded2013
Last FundingNov 23, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.